Effect of Two Different Doses of Dexmedetomidine Infusion in Morbidly Obese Patients
- Conditions
- AnesthesiaDexmedetomidineObesity, Morbid
- Interventions
- Registration Number
- NCT06018948
- Lead Sponsor
- Tanta University
- Brief Summary
Compare the effects of two different doses of dexmedetomidine infusion on oxygenation as a primary outcome and on lung mechanics, quality of recovery and perioperative analgesia as secondary outcomes in morbidly obese patients with restrictive lung disease undergoing abdominal surgery.
- Detailed Description
Dexmedetomidine is a selective α2 receptor agonist and has sympatholytic, analgesic, anti-inflammatory and sedative properties. Dexmedetomidine decreased dead space and improved both lung compliance and oxygenation in chronic obstructive pulmonary disease (COPD) patients undergoing lung cancer surgery.
The effects of dexmedetomidine on oxygenation and lung mechanics had been investigated in obstructive lung disease, but there are little information about its effect in morbidly obese patients with restrictive lung disease .
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
- Body Mass Index above 40 kg/m2 with restrictive lung disease((forced vital capacity) <70% in pre-operative pulmonary function tests), of American Society of anesthesiologists (ASA) physical status II and III.
- Aged 18-50 years.
- Scheduled for abdominal surgery.
- Patients with Forced expiratory volume1/forced vital capacity<7.
- Uncontrolled cardiac, respiratory, hepatic or renal diseases.
- Allergy to the study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dexmedetomidine 0.6 group Dexmedetomidine 0.6 patients will receive a bolus dose of 1µg/kg dexmedetomidine15 minute after endotracheal intubation over 10 minutes followed by continuous infusion of 0.6 mic/kg/hour for one hour. Control group Saline Patients will receive comparable volume of normal saline (0.9%) 15 minute after endotracheal intubation. Dexmedetomidine 0.3group Dexmedetomidine 0.3 patients will receive a bolus dose of 1µg/kg dexmedetomidine 15 minute after endotracheal intubation over 10 minutes followed by continuous infusion of 0.3 mic/kg/hour for one hour.
- Primary Outcome Measures
Name Time Method Intraoperative oxygenation Intraoperative Intraoperative oxygenation was assessed by P/F ratio (Arterial oxygen tension/fraction of inspired oxygen) at baseline and the end of drug infusion.
- Secondary Outcome Measures
Name Time Method Dynamic Lung compliance Intraoperative Dynamic lung compliance=tidal volume/ (peak airway pressure- Positive end-expiratory pressure).
Quality of recovery score 24 hours Postoperatively The Quality of recovery score scale provides a score ranging from 0 to 150, with a high score indicating a good quality of recovery
Time to first rescue analgesia 24 hours Postoperatively Time to first rescue analgesia as morphine consumption was recorded
Plateau pressure Intraoperative Plateau pressure was calculated by increasing end inspiratory pause to 30-40%.
Lung compliance 24 hours compliance = dynamic compliance at the end of the drug infusion - baseline dynamic compliance.
Post-operative pain 24 hour postoperatively Assessment of post-operative pain by The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme
Dead space (dead space to tidal volume) Intraoperative Physiological dead space was calculated by Hardman and Aitkenhead equation: (dead space to tidal volume) = 1.14(PaCO2 -EtCO2)/PaCO2- 0.005 dead space (%) = dead space by end of infusion - dead space at the base line / dead space by the end of drug infusion %
Static lung compliance Intraoperative Static lung compliance =tidal volume /(plateau pressure - Positive end-expiratory pressure).
Trial Locations
- Locations (1)
Tanta University
🇪🇬Tanta, El-Gharbia, Egypt